Tag
The 2026 Breakthrough Prizes awarded US$3 million each to researchers behind anomalous muon magnetic measurements and gene-therapy advances. The physics award spans hundreds of scientists across more than 30 institutions, underscoring the collaborative scale of modern particle physics. Both prizes signal elevated peer
Roche is launching a new Phase III placebo-controlled trial for DMD gene therapy Elevidys after the EMA rejected the treatment last year following two patient deaths. The 72-plus-week study of roughly 100 boys is designed to meet the EMA's data requirements for a regulatory re-submission. A successful outcome would
Evercore has held its positive rating on MeiraGTx Holdings (MGTX) while conducting broader revisions across the gene therapy and biotech sector. The maintained stance signals analyst differentiation of MGTX from peers subject to downward reassessment. No specific price target or catalyst was disclosed in the current
Tag
The 2026 Breakthrough Prizes awarded US$3 million each to researchers behind anomalous muon magnetic measurements and gene-therapy advances. The physics award spans hundreds of scientists across more than 30 institutions, underscoring the collaborative scale of modern particle physics. Both prizes signal elevated peer
2mo ago · 1 min · Technology
Roche is launching a new Phase III placebo-controlled trial for DMD gene therapy Elevidys after the EMA rejected the treatment last year following two patient deaths. The 72-plus-week study of roughly 100 boys is designed to meet the EMA's data requirements for a regulatory re-submission. A successful outcome would
2mo ago · 2 min · Business
Evercore has held its positive rating on MeiraGTx Holdings (MGTX) while conducting broader revisions across the gene therapy and biotech sector. The maintained stance signals analyst differentiation of MGTX from peers subject to downward reassessment. No specific price target or catalyst was disclosed in the current
2mo ago · 1 min · Markets
— End of feed —